Advancing Clinical Trials through Accuracy, Precision and Follow-Through
There is a wide gap between research participation and research awareness amongst both potential research participants and community physicians alike. Arrow Clinical Trials was founded in 2020 to bridge this gap by broadening awareness and access. The concept of viewing clinical research as a care option is an industry-wide push to help close the gap. By integrating clinical research as a potential supplemental treatment option, physicians and patients can gain a better understanding of the solutions and care options available in research trials.
Our seasoned clinical team has a combined trials experience of over 50 years spanning across hundreds of clinical trials, including nearly every indication.
At first glance, the drug development process might seem overly complex. However, each clinical trial that is performed in humans can be distilled to the following four phases. Arrow performs clinical trials in all of these phases:
First-in-Human studies that accepts healthy volunteers to determine acceptable dose of drug compound to test with a larger population.
Generally, these studies are performed with a small subset of people with a specific indication to closely evaluate safety and efficacy of the drug compound in the target indication.
Large-scale studies evaluating the safety and effectiveness of a compound based on encouraging results from the Phase II subset.
These studies occur after the FDA has approved the drug compound for public use based on Phase III results. These are generally long-term observational studies to assess continued safety and efficacy of the approved compound.
David Billmeier, M.D. is a board-certified Family Medicine and Hospice and Palliative Medicine doctor. He has been serving the greater Daytona area for over 25 years not only in his private practice, but also as Medical Director for Volusia Health Network with Halifax Health Hospital, and as a medical consultant for NASCAR and Porsche Racing. Dr. Billmeier has been involved in clinical research as both a principal investigator and sub-investigator for the past 10 years covering a broad range of therapeutic areas including central nervous system (CNS) with specific expertise in neurodegenerative disorders, metabolic and endocrine disorders, psychiatric disorders, dermatological disorders, and cardiological conditions to name some conditions of particular interest.